FDA Approves Combination NSAID/Opioid Seglentis
2 MIN READ
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA).
FDA Approves Combination NSAID/Opioid Seglentis
2 MIN READ
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA). Seglentis contains tramadol, a short-acting opioid, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for adults in the management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
2021 mPower Virtual Conference
On-Demand
The Mitchell | Genex | Coventry team looks forward to connecting with you at the 2021 mPower Conference, taking place virtually October 12–14, 2021.
Opioid Reduction Success
2 MIN READ
Opioid Reduction Success
2 MIN READ
As crises pile on, U.S. hospitals brace for a harrowing winter
5 MIN READ
The coronavirus pandemic is perhaps best depicted by the voids it carves rather than by what it yields. The disappearances of handshakes, rush hour traffic, and sellout crowds at sporting events reveal the outlines of a nation transformed.
AASP Northeast Trade Show
Visit Us at the Exhibit Booth Northeast is an event that has been designed to specifically fit the